We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+4.96%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.51B
AUM Growth
+$152M
Cap. Flow
+$148M
Cap. Flow %
9.78%
Top 10 Hldgs %
81.92%
Holding
39
New
5
Increased
6
Reduced
16
Closed
4
Avg Time Held
16.4 quarters
Top 10 Avg Time Held
4.7 quarters
Top 20 Avg Time Held
6 quarters

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$172M
2
ANNX icon
Annexon
ANNX
+$25.3M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10.1M
4
ALXO icon
ALX Oncology
ALXO
+$8.95M
5
PRME icon
Prime Medicine
PRME
+$6.05M

Top Sells

Rank Stock Value
1
RAPT icon
RAPT Therapeutics
RAPT
+$30M
2
COGT icon
Cogent Biosciences
COGT
+$27.7M
3
REPL icon
Replimune Group
REPL
+$10.7M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$7.41M
5
NRIX icon
Nurix Therapeutics
NRIX
+$5.99M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SRRK icon
1
Scholar Rock
SRRK
$5.01B
$446M 29.51%
9,066,621
+3,845,775
+74% +$172M
2018 Q2
31 quarters
KRYS icon
2
Krystal Biotech
KRYS
$9.58B
$174M 11.52%
673,505
-4,200
-0.6% -$1.12M
2018 Q4
29 quarters
STOK icon
3
Stoke Therapeutics
STOK
$1.48B
$136M 8.98%
4,164,120
+130,050
+3% +$4.27M
2019 Q2
27 quarters
IMNM icon
4
Immunome
IMNM
$2.09B
$122M 8.05%
5,558,885
-159,500
-3% -$3.55M
2023 Q4
9 quarters
NRIX icon
5
Nurix Therapeutics
NRIX
$2.33B
$120M 7.94%
7,732,808
-361,100
-4% -$5.99M
2020 Q3
22 quarters
ANNX icon
6
Annexon
ANNX
$726M
$80.6M 5.34%
14,549,768
+4,499,124
+45% +$25.3M
2020 Q3
22 quarters
ADCT icon
7
ADC Therapeutics
ADCT
$216M
$58M 3.84%
15,470,502
-196,229
-1% -$774K
2020 Q2
23 quarters
RGNX icon
8
Regenxbio
RGNX
$479M
$36.6M 2.42%
4,368,804
– –
2017 Q1
36 quarters
STTK icon
9
Shattuck Labs
STTK
$585M
$35.6M 2.36%
5,539,724
– –
2020 Q4
21 quarters
BEAM icon
10
Beam Therapeutics
BEAM
$2.54B
$29.5M 1.95%
1,237,659
-48,200
-4% -$1.34M
2020 Q1
24 quarters
NGNE icon
11
Neurogene
NGNE
$466M
$29.4M 1.95%
1,459,599
– –
2019 Q4
25 quarters
COGT icon
12
Cogent Biosciences
COGT
$4.98B
$26.5M 1.75%
688,036
-749,882
-52% -$27.7M
2023 Q2
11 quarters
ABSI icon
13
Absci
ABSI
$1.61B
$24.8M 1.64%
8,253,316
– –
2021 Q3
18 quarters
IDYA icon
14
IDEAYA Biosciences
IDYA
$3.38B
$17.4M 1.15%
521,117
-220,900
-30% -$7.41M
2023 Q4
9 quarters
ALXO icon
15
ALX Oncology
ALXO
$156M
$16M 1.06%
7,964,188
+4,699,470
+144% +$8.95M
2020 Q3
22 quarters
FATE icon
16
Fate Therapeutics
FATE
$247M
$15.4M 1.02%
12,872,946
– –
2015 Q2
43 quarters
XENE icon
17
Xenon Pharmaceuticals
XENE
$3.41B
$15.3M 1.01%
262,674
+128,792
+96% +$5.93M
2025 Q4
1 quarter
SLDB icon
18
Solid Biosciences
SLDB
$674M
$14.5M 0.96%
2,011,895
+151,353
+8% +$973K
2024 Q4
5 quarters
NUVB icon
19
Nuvation Bio
NUVB
$1.7B
$13.5M 0.9%
3,153,256
-10,000
-0.3% -$55.7K
2021 Q1
20 quarters
ZYME icon
20
Zymeworks
ZYME
$1.82B
$12.3M 0.82%
491,654
– –
2020 Q1
24 quarters
SLN icon
21
Silence Therapeutics
SLN
$579M
$11.4M 0.76%
2,164,777
– –
2024 Q1
8 quarters
DBVT icon
22
DBV Technologies S.A. American Depositary Shares
DBVT
$571M
$10.3M 0.68%
491,340
-58,500
-11% -$1.22M
2025 Q4
1 quarter
BMRN icon
23
BioMarin Pharmaceuticals
BMRN
$10.6B
$9.82M 0.65%
+173,859
New +$10.1M
2026 Q1
0 quarters
CLDX icon
24
Celldex Therapeutics
CLDX
$2.24B
$8.3M 0.55%
261,508
-21,800
-8% -$594K
2020 Q2
23 quarters
CBLL icon
25
CeriBell Inc
CBLL
$997M
$7.09M 0.47%
386,786
-48,453
-11% -$974K
2024 Q4
5 quarters
1
2

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2026 Portfolio in Review

As of Q1 2026, Redmile Group held 39 positions worth $1.51B, up 11% from $1.36B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Redmile Group deployed $148M of net new capital in Q1 2026, opening 5 new positions and adding to 6 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 173,859 shares worth $9.82M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Cogent Biosciences, an estimated $27.7M trimmed.

  • Redmile Group's largest Q1 2026 buy was BioMarin Pharmaceuticals: 173,859 shares worth $9.82M.
  • Redmile Group added most to Scholar Rock in Q1 2026, an estimated $172M increase.
  • Redmile Group's biggest Q1 2026 reduction was Cogent Biosciences, cutting an estimated $27.7M.
  • Redmile Group fully exited RAPT Therapeutics in Q1 2026, selling an estimated $30M.
  • Redmile Group's ten largest holdings make up 82% of its $1.51B portfolio in Q1 2026.
  • Redmile Group opened 5 new positions and closed 4 in Q1 2026.
  • Redmile Group's portfolio value rose 11% quarter-over-quarter to $1.51B.

Based on Redmile Group's 13F filing for Q1 2026, filed 15 May 2026.